source
- FDA releases FY 2027 user fee rates and updates guidance for injectable peptide ANDAsThe U.S. Food and Drug Administration has published its user fee rates for fiscal year 2027, covering prescription drugs, generics, biosimilars, medical devices and over‑the‑counter products. The r…
- Attovia, Braveheart Bio, and Vogenx aim to raise over $500M through combined IPOsAttovia Therapeutics, Braveheart Bio and Vogenx have each filed IPO paperwork, setting price ranges that together target more than $500 million in gross proceeds from public investors. Braveheart…